id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1225148,d7ddb76b-e396-4a4b-9476-e413f0eb9bf0,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WOMEN'S INTERNATIONAL PHARMACY, INC.",2012,first_quarter,HCR,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.  No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation introduced yet.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-04-11T15:52:23.123000-04:00
1225149,d7ddb76b-e396-4a4b-9476-e413f0eb9bf0,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WOMEN'S INTERNATIONAL PHARMACY, INC.",2012,first_quarter,PHA,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.  No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation introduced yet.

Regulatory issues involving compounded 17P.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-04-11T15:52:23.123000-04:00
1225150,d7ddb76b-e396-4a4b-9476-e413f0eb9bf0,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WOMEN'S INTERNATIONAL PHARMACY, INC.",2012,first_quarter,MED,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.  No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation introduced yet.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-04-11T15:52:23.123000-04:00
1225151,d7ddb76b-e396-4a4b-9476-e413f0eb9bf0,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WOMEN'S INTERNATIONAL PHARMACY, INC.",2012,first_quarter,LAW,"Proposals to amend the Controlled Substances Act to clarify the definition of ""dispense"" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice.  No specific legislation yet.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-04-11T15:52:23.123000-04:00